Related Experiment Videos
Familial hypercholesterolaemia and LDL receptor mutations
1MRC Lipoprotein Team, Hammersmith Hospital, London, UK.
Insights
Familial hypercholesterolaemia (FH) results from inherited defects in the low-density lipoprotein (LDL)-receptor gene, leading to high cholesterol and premature heart disease. Genetic mutations vary, complicating diagnosis and treatment assessment.
Area of Science:
- Biochemistry
- Genetics
- Cardiovascular Medicine
Background:
- Familial hypercholesterolaemia (FH) is an inherited disorder.
- It is caused by defects in the low-density lipoprotein (LDL)-receptor gene.
- This leads to impaired LDL catabolism and elevated plasma LDL cholesterol levels.
Purpose of the Study:
- To investigate the genetic basis of familial hypercholesterolaemia.
- To understand the relationship between LDL receptor gene mutations, protein structure, and function.
- To explore the implications of genetic heterogeneity for disease diagnosis and treatment.
Main Methods:
- Analysis of LDL receptor gene mutations in FH patients.
- Correlating specific mutations with clinical phenotypes.
- Investigating the impact of genetic variation on LDL metabolism.
Main Results:
- Numerous different mutations in the LDL receptor gene have been identified in FH patients.
- This genetic heterogeneity provides insights into LDL receptor protein structure-function relationships.
- Simple DNA-based diagnosis is challenging due to mutation diversity.
Conclusions:
- Genetic defects in the LDL receptor gene cause FH, leading to atherosclerosis and early heart disease.
- The wide spectrum of mutations complicates diagnosis and personalized treatment strategies.
- Further research with defined mutation groups is needed to assess mutation impact on disease severity and treatment response.
Abstract:
Inherited defects in the gene for the low density lipoprotein (LDL)-receptor give rise to familial hypercholesterolaemia (FH), a disorder in which defective catabolism of LDL causes a marked increase in its concentration in plasma. As a result, there is excessive deposition of cholesterol in the arterial wall leading to accelerated atherosclerosis and premature coronary heart disease in most patients, although there are differences in its severity. Many different mutations have been found in the LDL receptor genes of FH patients, and although this heterogeneity has provided information about the relationship between structure and function in different domains of the protein, it makes simple DNA-based diagnosis of the disease impossible. When sufficient groups of patients with defined mutations are available it will be possible to determine the relative importance of any particular mutation compared with other genetic or environmental factors in relation to the severity of their symptoms or their response to treatment.